Ocata Therapeutics is focused on the development and commercialization of regenerative medicine and cell therapy technologies.
Business Model:
Revenue: $337k
Employees: 11-50
Ocata Therapeutics was acquired by
Astellas Pharma.
The acquisition happend on 2015-11-10.
Details of the transaction were not public
Address: 33 Locke Dr
City: Marlborough
State: MA
Zip: 01752
Country: US
Ocata Therapeutics is focused on the development and commercialization of regenerative medicine and cell therapy technologies.
Contact Phone:
+15087561212
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
2/11/2005
Ticker Symbol:
OCAT
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 8/2015 | Debt | $6M |
Silicon Valley Bank |
11/2009 | Post-IPO Debt | $2.8M | 8/2015 | Post-IPO Debt | 1 | $10M |
Silicon Valley Bank Silicon Valley Bank |
7/2014 | Post-IPO Equity | 1 | $30M |
Lincoln Park Capital Fund Lincoln Park Capital Fund Lincoln Park Capital Fund |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|